LILLE COVID RESEARCH NETWORK (Covid-19)

NCT04475211 | Completed

• 2 other identifiers: 2020_542020-A01514-35
• Study Type: observational
• Target: 757
• Locations: 1 country
• Sites: 1

Brief Summary

The Lille University Hospital developped a research objective common to all the services which took care of patients, "suspected patient", "possible case", "probable case" or "confirmed case" infected with SARS-CoV-2 by constituting a prospective and a retrospective observational cohort which allowed pooling and sharing the resources and data collected. In the next two years the prospective cohort will allow to continue inclusions in a standardized way mainly for the constitution of a negative control group (excluded cases), to collect biological samples which had not been collected in the retrospective cohort so that the pathophysiology of the COVID-19 will be better apprehended as for example the inflammatory response to the viral infection. Finally in case of a second epidemic wave in the Hauts De France, it seems essential to have a defined research protocol which had already received all the necessary authorizations to guarantee cutting-edge (or quality ) research in a center like the Lille University Hospital.The aim objective of this study is to identify predictive factors of mortality to day 28 infection to SARS-CoV-2 for patients under medical care for the COVID-19 in the Lille University Hospital thanks to the constitution of an epidemiological, clinical, biological, immunological, genetic, microbiological, anatomopathologic, radiological, therapeutic database and so record the results of functional exploration exams.

Conditions

Sars-CoV2

Keywords

COVID-19; fatality rate; Inflammatory and autoimmune processes; severity; clinical features; diagnostic (qRT-PCR or serology) methods; thrombosis; co-infection

Outcome Measures

Primary Outcomes (1)

• Number of patients "confirmed cases" of SARS-CoV-2 infection who died at D28 of inclusion

  Identify predictors of mortality at day 28 in patients treated at the Lille University Hospital for COVID-19

  At 28 days

Secondary Outcomes (11)

• Correlation between Infection characteristics of patients at inclusion and all predictors for Covid-19

  At inclusion (day 0)

• Correlation between evolution infection characteristics of patients during stay of hospitalisation and all predictors for Covid-19

  At inclusion ( day 0) ,at day 1 , day3±1, Day 5±1, day 7±1, day 9±2, day14±2, day30±3, at months 3±7 days and at months6±7days or until death

• Positivity for Covid-19 patients performed and all predictors for Covid-19

  At inclusion (day 0)

• Correlation between hospitalisation and all predictors for Covid-19

  At inclusion( Day 0)

• Correlation between risk factors measured at D0 for severe CoV-2 SARS infection and all predictors for Covid-19

  At 28 day

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All adult "suspect patient", "possible case", "probable case" or "confirmed case" of an SARS-CoV-2 infection admitted to Lille University Hospital.

You may qualify if:

• All adult "suspect patient", "possible case", "probable case" or "confirmed case" of an SARS-CoV-2 infection admitted to Lille University Hospital.

You may not qualify if:

• Minor patient Patient under guardianship or curatorship Refusal to participate in the study Patient for whom the collection of genetic non-opposition or consent is impossible because of a language barrier with the patient himself or herself or with his or her trusted person or close family.
• Translated with www.DeepL.com/Translator (free version)

Sponsors & Collaborators

• University Hospital, Lille: lead

Study Sites (1)

Hop Claude Huriez Chr Lille

Lille, 59037, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood, plasma, serum

MeSH Terms

Conditions

COVID-19; Disease; Thrombosis; Coinfection

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Marie-Charlotte CHOPIN, MD

  University Hospital, Lille

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 10, 2020
• First Posted: July 17, 2020
• Study Start: August 10, 2020
• Primary Completion: June 15, 2022
• Study Completion: June 15, 2022
• Last Updated: December 23, 2025

Record last verified: 2025-12

Locations

FR (1)